Symbols / IMMP Stock $0.44 -1.28% Immutep Limited

Healthcare • Biotechnology • Australia • NGM
IMMP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Marc Voigt
Exch · Country NGM · Australia
Market Cap 64.68M
Enterprise Value 548.90M
Income -83.92M
Sales 7.92M
FCF (ttm) -35.68M
Book/sh 0.48
Cash/sh 0.07
Employees —
Insider 10d —
IPO Apr 19, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.00
PEG —
P/S 8.16
P/B 0.91
P/C —
EV/EBITDA -6.66
EV/Sales 69.28
Quick Ratio 2.91
Current Ratio 2.97
Debt/Eq 1.22
LT Debt/Eq —
EPS (ttm) -0.41
EPS next Y -0.22
EPS Growth —
Revenue Growth 91.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-09-02
Earnings (prior) —
ROA -32.10%
ROE -61.85%
ROIC —
Gross Margin 0.00%
Oper. Margin -7.64%
Profit Margin 0.00%
Shs Outstand 147.37M
Shs Float 1.28B
Insider Own 0.01%
Instit Own 2.43%
Short Float 3.59%
Short Ratio 0.15
Short Interest 5.14M
52W High 3.53
vs 52W High -87.57%
52W Low 0.29
vs 52W Low 51.34%
Beta 2.36
Impl. Vol. 0.00%
Rel Volume 0.05
Avg Volume 14.26M
Volume 678.49K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.44
Price $0.44
Change -1.28%
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-4.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 down Citizens Market Outperform → Market Perform —
2026-03-13 down Baird Outperform → Neutral $1
2026-02-23 init Citizens — → Market Outperform $10
2026-02-17 init Citizens — → Market Outperform $6
2024-11-15 main Baird Outperform → Outperform $7
2024-06-27 main Baird Outperform → Outperform $6
2024-05-17 init Capital One — → Overweight $10
2023-08-28 reit Baird Outperform → Outperform $7
2023-08-03 init Baird — → Outperform $7
2023-08-03 init Baird — → Outperform $7
2023-05-18 main Maxim Group Buy → Buy $10
2021-08-03 init Ladenburg Thalmann — → Buy $8
2018-05-29 main Maxim Group Buy → Buy $7
News
RSS: Latest IMMP news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total Revenue
0.00
0.00
-100.00%
0.17
0.00
Operating Revenue
0.00
0.00
-100.00%
0.17
0.00
Operating Expense
46.56
+12.37%
41.43
+21.83%
34.01
+73.01%
19.66
Research And Development
41.55
+14.59%
36.26
+15.68%
31.34
+81.83%
17.24
Selling General And Administration
8.85
+1.99%
8.68
+20.38%
7.21
+14.77%
6.28
General And Administrative Expense
8.85
+1.99%
8.68
+20.38%
7.21
+14.77%
6.28
Other Gand A
8.85
+1.99%
8.68
+20.38%
7.21
+14.77%
6.28
Other Operating Expenses
-3.84
-9.59%
-3.51
+22.85%
-4.54
-17.63%
-3.86
Total Expenses
46.56
+12.37%
41.43
+21.83%
34.01
+73.01%
19.66
Operating Income
-46.56
-12.37%
-41.43
-22.44%
-33.84
-72.15%
-19.66
EBITDA
-42.69
-7.05%
-39.88
-24.15%
-32.12
-7.45%
-29.89
Normalized EBITDA
-42.80
-5.34%
-40.63
-19.72%
-33.94
-63.77%
-20.72
Reconciled Depreciation
—
—
3.00
—
EBIT
-42.69
-7.05%
-39.88
-24.15%
-32.12
-7.45%
-29.89
Total Unusual Items
0.11
-84.98%
0.76
-58.48%
1.82
+119.84%
-9.17
Total Unusual Items Excluding Goodwill
0.11
-84.98%
0.76
-58.48%
1.82
+119.84%
-9.17
Net Income
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Pretax Income
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Net Non Operating Interest Income Expense
3.85
+319.35%
0.92
+595.43%
0.13
+38.31%
0.10
Interest Expense Non Operating
0.03
+49.96%
0.02
-77.93%
0.09
+840.76%
0.01
Net Interest Income
3.85
+319.35%
0.92
+595.43%
0.13
+38.31%
0.10
Interest Expense
0.03
+49.96%
0.02
-77.93%
0.09
+840.76%
0.01
Interest Income Non Operating
3.88
+313.50%
0.94
+318.23%
0.22
+113.16%
0.11
Interest Income
3.88
+313.50%
0.94
+318.23%
0.22
+113.16%
0.11
Other Income Expense
-0.01
-101.84%
0.62
-58.76%
1.49
+114.45%
-10.34
Other Non Operating Income Expenses
-0.12
+10.26%
-0.14
+57.18%
-0.32
+72.29%
-1.17
Gain On Sale Of Security
0.11
-84.98%
0.76
-58.48%
1.82
+119.84%
-9.17
Tax Provision
0.00
0.00
-100.00%
0.00
+3.03%
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.55
+119.84%
-2.75
Net Income Including Noncontrolling Interests
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Net Income From Continuing Operation Net Minority Interest
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Net Income From Continuing And Discontinued Operation
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Net Income Continuous Operations
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Normalized Income
-42.83
-5.36%
-40.65
-21.41%
-33.48
-42.59%
-23.48
Net Income Common Stockholders
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Diluted EPS
-0.36
+20.36%
-0.45
-17.94%
-0.38
—
Basic EPS
-0.36
+20.36%
-0.45
-17.94%
-0.38
—
Basic Average Shares
120.11
+34.59%
89.24
+5.12%
84.90
—
Diluted Average Shares
120.11
+34.59%
89.24
+2.54%
87.03
—
Diluted NI Availto Com Stockholders
-42.72
-7.07%
-39.90
-23.86%
-32.21
-7.72%
-29.90
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total Assets
201.58
+36.71%
147.45
+44.32%
102.17
+24.55%
82.03
Current Assets
191.35
+41.78%
134.97
+48.62%
90.81
+32.73%
68.42
Cash Cash Equivalents And Short Term Investments
181.88
+47.37%
123.42
+54.28%
80.00
+33.04%
60.13
Cash And Cash Equivalents
161.79
+31.09%
123.42
+54.28%
80.00
+33.04%
60.13
Cash Equivalents
66.86
+1763.24%
3.59
+1088.14%
0.30
-96.35%
8.28
Cash Financial
94.93
-20.78%
119.83
+50.36%
79.69
+53.71%
51.85
Other Short Term Investments
20.09
0.00
—
—
Receivables
7.56
-5.20%
7.97
-4.78%
8.37
+36.73%
6.12
Accounts Receivable
0.01
-95.99%
0.13
+652.83%
0.02
-66.17%
0.05
Other Receivables
6.30
+3.98%
6.06
-3.30%
6.27
+18.32%
5.30
Taxes Receivable
1.25
-29.77%
1.78
-14.68%
2.09
+169.33%
0.78
Accrued Interest Receivable
—
0.02
+48906.98%
0.00
-75.98%
0.00
Prepaid Assets
1.92
-46.41%
3.57
+46.32%
2.44
+43.55%
1.70
Restricted Cash
0.00
0.00
0.00
-100.00%
0.47
Total Non Current Assets
10.23
-18.06%
12.48
+9.91%
11.36
-16.56%
13.61
Net PPE
0.68
+45.08%
0.47
+52.08%
0.31
-0.52%
0.31
Gross PPE
1.37
+23.22%
1.11
+18.29%
0.94
+0.19%
0.94
Accumulated Depreciation
-0.69
-7.34%
-0.64
-1.85%
-0.63
-0.54%
-0.63
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.62
+60.00%
0.39
+42.65%
0.27
+0.50%
0.27
Machinery Furniture Equipment
0.76
+3.75%
0.73
+8.48%
0.67
+0.06%
0.67
Goodwill And Other Intangible Assets
8.24
-13.16%
9.49
-10.08%
10.55
-17.85%
12.85
Goodwill
0.11
+0.00%
0.11
+0.00%
0.11
+0.00%
0.11
Other Intangible Assets
8.13
-13.32%
9.38
-10.19%
10.44
-18.00%
12.74
Non Current Prepaid Assets
1.31
-48.19%
2.52
+409.40%
0.50
+9.13%
0.45
Total Liabilities Net Minority Interest
12.06
+9.82%
10.98
+35.68%
8.09
-7.61%
8.76
Current Liabilities
10.49
+7.31%
9.77
+52.34%
6.41
+20.12%
5.34
Payables And Accrued Expenses
9.56
+5.96%
9.02
+56.89%
5.75
+20.30%
4.78
Payables
4.22
-27.30%
5.80
+0.88%
5.75
+20.30%
4.78
Accounts Payable
3.79
-30.43%
5.45
+90.09%
2.87
+57.06%
1.82
Other Payable
0.43
+20.82%
0.35
-87.70%
2.89
-2.39%
2.96
Current Accrued Expenses
5.34
+65.86%
3.22
—
—
Employee Benefits
0.20
+23.56%
0.16
+40.24%
0.12
+31.87%
0.09
Pensionand Other Post Retirement Benefit Plans Current
0.69
+22.81%
0.56
+57.49%
0.36
+1.97%
0.35
Current Debt And Capital Lease Obligation
0.23
+26.14%
0.19
+6.82%
0.17
-16.72%
0.21
Current Capital Lease Obligation
0.23
+26.14%
0.19
+6.82%
0.17
-16.72%
0.21
Other Current Liabilities
—
—
0.13
—
Total Non Current Liabilities Net Minority Interest
1.57
+30.12%
1.21
-28.03%
1.68
-50.93%
3.42
Long Term Debt And Capital Lease Obligation
1.36
+30.40%
1.04
-33.16%
1.56
-40.14%
2.61
Long Term Debt
0.96
+15.00%
0.84
-42.50%
1.45
-42.50%
2.53
Long Term Capital Lease Obligation
0.40
+92.38%
0.21
+93.15%
0.11
+34.18%
0.08
Long Term Provisions
0.01
—
—
—
Non Current Deferred Liabilities
0.00
0.00
0.00
0.00
Non Current Deferred Taxes Liabilities
0.00
0.00
0.00
0.00
Stockholders Equity
189.52
+38.87%
136.47
+45.06%
94.08
+28.40%
73.27
Common Stock Equity
189.52
+38.87%
136.47
+45.06%
94.08
+28.40%
73.27
Capital Stock
542.11
+21.47%
446.27
+21.47%
367.41
+17.22%
313.42
Common Stock
542.11
+21.47%
446.27
+21.47%
367.41
+17.22%
313.42
Share Issued
1,452.61
+21.23%
1,198.27
+34.94%
888.01
+15.78%
766.95
Ordinary Shares Number
1,452.61
+21.23%
1,198.27
+34.94%
888.01
+15.78%
766.95
Retained Earnings
-382.65
-12.57%
-339.93
-12.43%
-302.34
-10.08%
-274.64
Gains Losses Not Affecting Retained Earnings
30.06
-0.21%
30.13
+3.87%
29.00
-15.91%
34.49
Total Equity Gross Minority Interest
189.52
+38.87%
136.47
+45.06%
94.08
+28.40%
73.27
Total Capitalization
190.48
+38.73%
137.30
+43.73%
95.53
+26.03%
75.80
Working Capital
180.86
+44.47%
125.19
+48.34%
84.40
+33.80%
63.08
Invested Capital
190.48
+38.73%
137.30
+43.73%
95.53
+26.03%
75.80
Total Debt
1.59
+29.76%
1.23
-29.16%
1.73
-38.41%
2.82
Capital Lease Obligations
0.63
+61.15%
0.39
+39.86%
0.28
-2.58%
0.29
Net Tangible Assets
181.28
+42.76%
126.98
+52.03%
83.52
+38.23%
60.42
Tangible Book Value
181.28
+42.76%
126.98
+52.03%
83.52
+38.23%
60.42
Derivative Product Liabilities
—
0.00
0.00
-100.00%
0.72
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Cash Flow
—
—
-43.94
—
Cash Flow From Continuing Operating Activities
—
—
-43.94
—
Net Income From Continuing Operations
—
—
-46.82
—
Depreciation Amortization Depletion
—
—
3.00
—
Depreciation And Amortization
—
—
3.00
—
Other Non Cash Items
—
—
0.47
—
Stock Based Compensation
—
—
2.16
—
Operating Gains Losses
—
—
-0.48
—
Gain Loss On Investment Securities
—
—
-0.86
—
Net Foreign Currency Exchange Gain Loss
—
—
0.38
—
Change In Working Capital
—
—
-2.27
—
Change In Receivables
—
—
-3.27
—
Change In Payables And Accrued Expense
—
—
2.09
—
Change In Payable
—
—
2.09
—
Change In Other Working Capital
—
—
0.05
—
Change In Other Current Assets
—
—
-1.14
—
Investing Cash Flow
-21.02
-25304.82%
-0.08
-261.07%
-0.02
-46.88%
-0.02
Cash Flow From Continuing Investing Activities
-21.02
-25304.82%
-0.08
-261.07%
-0.02
-46.88%
-0.02
Net PPE Purchase And Sale
-0.03
+64.69%
-0.08
-261.07%
-0.02
-46.88%
-0.02
Purchase Of PPE
-0.03
+64.69%
-0.08
-261.07%
-0.02
-46.88%
-0.02
Capital Expenditure
-0.93
-1026.93%
-0.08
-261.07%
-0.02
-46.88%
-0.02
Net Investment Purchase And Sale
-20.09
0.00
0.00
—
Purchase Of Investment
-20.09
0.00
0.00
—
Net Intangibles Purchase And Sale
-0.90
0.00
0.00
—
Purchase Of Intangibles
-0.90
0.00
0.00
—
Financing Cash Flow
95.18
+25.20%
76.02
+51.06%
50.33
-4.47%
52.68
Cash Flow From Continuing Financing Activities
95.18
+25.20%
76.02
+51.06%
50.33
-4.47%
52.68
Net Issuance Payments Of Debt
-0.23
-6.85%
-0.21
+4.75%
-0.22
-3.81%
-0.21
Repayment Of Debt
-0.23
-6.85%
-0.21
+4.75%
-0.22
-3.81%
-0.21
Long Term Debt Payments
-0.23
-6.85%
-0.21
+4.75%
-0.22
-3.81%
-0.21
Net Long Term Debt Issuance
-0.23
-6.85%
-0.21
+4.75%
-0.22
-3.81%
-0.21
Net Common Stock Issuance
100.24
+25.16%
80.08
+51.17%
52.98
+22.32%
43.31
Proceeds From Stock Option Exercised
—
0.00
0.00
-100.00%
11.27
Net Other Financing Charges
-4.83
-25.47%
-3.85
-58.57%
-2.43
-44.53%
-1.68
Changes In Cash
39.34
-3.06%
40.58
+102.18%
20.07
-42.69%
35.02
Effect Of Exchange Rate Changes
-0.97
-134.09%
2.84
+523.09%
-0.67
+10.87%
-0.75
Beginning Cash Position
123.42
+54.28%
80.00
+32.02%
60.59
+130.20%
26.32
End Cash Position
161.79
+31.09%
123.42
+54.28%
80.00
+32.02%
60.59
Free Cash Flow
-35.75
-0.89%
-35.44
-17.14%
-30.25
-71.35%
-17.66
Cash Flowsfromusedin Operating Activities Direct
-34.82
+1.51%
-35.36
-16.96%
-30.23
-71.37%
-17.64
Classesof Cash Payments
-42.45
-6.14%
-39.99
-18.18%
-33.84
-73.41%
-19.51
Classesof Cash Receiptsfrom Operating Activities
3.96
+5.99%
3.74
+7.51%
3.48
+95.90%
1.77
Common Stock Issuance
100.24
+25.16%
80.08
+51.17%
52.98
+22.32%
43.31
Interest Paid Direct
-0.03
-46.09%
-0.02
+77.78%
-0.09
-602.68%
-0.01
Interest Received Direct
3.70
+302.57%
0.92
+308.62%
0.22
+100.15%
0.11
Issuance Of Capital Stock
100.24
+25.16%
80.08
+51.17%
52.98
+22.32%
43.31
Other Cash Receiptsfrom Operating Activities
0.20
+142.04%
0.08
-5.37%
0.09
-73.03%
0.32
Paymentsto Suppliersfor Goodsand Services
-42.45
-6.14%
-39.99
-18.18%
-33.84
-73.41%
-19.51
Receiptsfrom Customers
0.00
0.00
-100.00%
0.09
-36.51%
0.14
Receiptsfrom Government Grants
3.76
+2.92%
3.66
+10.71%
3.30
+151.31%
1.31
Taxes Refund Paid Direct
0.00
0.00
+100.00%
-0.00
-3.03%
-0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category